



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 13th September, 2017

To,

The Manager
Listing Department
The Bombay Stock Exchange Ltd,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 524414

Sub: Submission of Revised Standalone Unaudited Financial Results in Compliance with Regulation 33 of SEBI (LODR) Regulations, 2015

Ref: You're mailed dated 12.09.2017.

Dear Sir/Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we submit herewith the following:

1. Revised Standalone Unaudited Financial Results of the Company for the quarter ended 30th June, 2017.
2. Limited Review Report by Statutory Auditors on Unaudited Financial Results for the quarter ended 30th June, 2017

Thanking you,

Yours faithfully,

For **NORRIS MEDICIENS LIMITED**

Vinay Rana
(Company Secretary)



STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2017

Sr. No.	Particulars	(Rs. In Lacs)			
		Quarter ended			Year ended
		3 months ended	Preceding 3 months ended	Corrospounding 3 month ended in previous year	Previous year ended
		30-06-2017 (Unaudited)	31-03-2017 (Audited)	30-06-2016 (Unaudited)	31-03-2017 (Audited)
1	Income from operation				
	Revenue from Operations	350.86	436.98	417.89	2045.68
	Other Income	0.57	12.38	0.07	13.96
	Total Income	351.43	449.36	417.96	2059.64
2	Expenses				
	(a) Cost of materials consumed	122.94	248.62	192.29	1052.05
	(b) Change in inventories of finished goods work in progress and stock-in-trade	46.23	-18.46	7.67	-11.97
	(c) Employee benefits expense	138.11	129.51	116.49	530.78
	(d) Finance cost	17.33	21.08	12.15	60.12
	(e) Depreciation and amortisation expense	16.15	21.10	14.50	64.60
	(f) Other Expense	101.41	142.90	97.48	482.36
	Total Expenses	442.17	544.75	440.58	2177.94
3	Profit / (Loss) before Tax	-90.74	-95.39	-22.62	-118.30
4	Tax Expense				
	(a) Current Tax	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	41.57	0.00	41.57
5	Profit / (Loss) after tax for the period	-90.74	-53.82	-22.62	-76.73
6	Other Comprehensive Income				
(a)	(i) Item that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to item that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
(b)	(i) Item that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to item that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
7	Total Comprehensive Income for the period	-90.74	-53.82	-22.62	-76.73
	Basic and Diluted Earning per equity share	-0.91	-0.54	-0.23	-0.77

Notes:

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 14.08.2017.
- The Company is having one segment only and therefore Segmental Reporting is not applicable.
- The above Results, have been prepared in accordance with Ind AS notified under the companies (Indian Accounting Standards) Rules, 2015.

Reconciliation of Net Profit between Previous GAAP and Ind AS:

Standalone Financial Results.

Nature of Adjustment	Rs. In Lacs
	Quarter Ended 30.06.2016
Net Profit Under Previous GAAP	(22.62)
Actuarial gain / (Loss) on employees defined benefit funds recognised in Other Comprehensive Income (Net)	-
Net gain / (Loss) on financial assets at fair value through profit and Loss	-
Net Profit under per Ind As	(22.62)

- Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with

For NORRIS MEDICINES LIMITED

Date : 14.08.2017
Place : Ahmedabad



Vimal D Shah
Managing Director

Review Report to the Board of Directors
Norris Medicines Limited
Ankleshwar.


We have reviewed the accompanying statement of unaudited financial results of **Norris Medicines Limited** ("the company") for the period ended 30th June, 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : BHARUCH
Date : 14th August, 2017

232, Rangoli Complex,
Station Road,
Bharuch - 392 001
Gujarat.

For, MINU MODI & CO.
Chartered Accountants

MINU MODI
Proprietor
M. No. 100289
(Firm Reg. No. 119948W)